^
Association details:
| Biomarker: | KRAS G12A |
|---|---|
| Cancer: | Non Small Cell Lung Cancer |
| Drug: | erlotinib (EGFR inhibitor) |
| Direction: | Resistant |
Evidence:
Source:
Title:
Mutations in the Epidermal Growth Factor Receptor and in KRAS Are Predictive and Prognostic Indicators in Patients With Non–Small-Cell Lung Cancer Treated With Chemotherapy Alone and in Combination With Erlotinib
Excerpt:
Patients with KRAS-mutant NSCLC showed poorer clinical outcomes when treated with erlotinib and chemotherapy....KRAS was successfully sequenced more often than EGFR because of the simpler sequencing strategy required. Single amino acid substitutions in codon 12 were most common (51 of 55), whereas codon 13 mutations were found in only four samples (Table 2 and Supplemental Fig 1).
DOI:
10.1200/JCO.2005.02.857
